Targeted Fusion-Guided Approach To Prostate Biopsy May Improve Detection Rates Of High-Risk Cancers

Posted: January 29, 2015

Medscape reports that research published in the Journal of the American Medical Association suggests that “a targeted fusion-guided approach to prostate biopsy improves detection rates of high-risk cancers while finding fewer low-risk cancers when compared with the standard approach of 12 core biopsy that is currently used in clinical practice.” This “new approach electronically superimposes magnetic resonance images onto standard transrectal ultrasound images in real time, and thus provides a three-dimensional map of the prostate.”

HealthDay reports that “the new technology…diagnosed 30 percent more high-risk cancers than standard prostate biopsies in men suspected of prostate cancer.” Additionally, “these MRI-targeted biopsies…were better at weeding out low-risk prostate cancers that would not lead to a man’s death, diagnosing 17 percent fewer low-grade tumors than standard biopsy, said senior author Dr. Peter Pinto,” who “is head of the prostate cancer section at the U.S. National Cancer Institute’s Center for Cancer Research in Bethesda, Md.”

Diagnostic Imaging reports that in a release, lead author Mohammad Minhaj Siddiqui, MD, said, “This study demonstrates that targeted fusion-guided biopsy could significantly enhance our ability to identify patients with high-risk prostate cancers that need more aggressive treatment.”